GAITHERSBURG, Md., May 12, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq:NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant, today announced that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ (NVX-CoV2373) into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.
Read more at prnewswire.comAccess to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
PR Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here